{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010031","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.539264+00:00","generated_at":"2026-05-17T21:28:50.980410+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"MetaVia partners with Syntekabio to use AI for new DA-1241 indications","bullets":["Collaboration leverages Syntekabio’s DeepMatcher platform to screen >1,700 protein targets for new DA-1241 indications.","Follows positive Phase 2a data in MASH; DA-1241 showed safety, hepatoprotective, and glucose-regulating effects.","No financial terms disclosed; initial insights expected later in 2025.","DA-1241 is a novel oral GPR119 agonist in clinical development for cardiometabolic diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010031","json":"https://secwatch.observer/filing/0001558370-25-010031.json","markdown":"https://secwatch.observer/filing/0001558370-25-010031.md","text":"https://secwatch.observer/filing/0001558370-25-010031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025010031/0001558370-25-010031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025010031/mtva-20250804x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:28:50.980410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}